Personalis Past Earnings Performance
Past criteria checks 0/6
Personalis's earnings have been declining at an average annual rate of -37.4%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-37.4%
Earnings growth rate
17.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 5.6% |
| Return on equity | -83.7% |
| Net Margin | -147.4% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Personalis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 73 | -108 | 50 | 65 |
| 30 Sep 23 | 71 | -113 | 54 | 68 |
| 30 Jun 23 | 67 | -110 | 57 | 66 |
| 31 Mar 23 | 69 | -114 | 61 | 64 |
| 31 Dec 22 | 65 | -113 | 64 | 65 |
| 30 Sep 22 | 69 | -102 | 60 | 63 |
| 30 Jun 22 | 76 | -94 | 57 | 62 |
| 31 Mar 22 | 80 | -81 | 53 | 57 |
| 31 Dec 21 | 85 | -65 | 48 | 49 |
| 30 Sep 21 | 85 | -58 | 45 | 43 |
| 30 Jun 21 | 83 | -50 | 41 | 37 |
| 31 Mar 21 | 80 | -45 | 37 | 32 |
| 31 Dec 20 | 79 | -41 | 62 | 29 |
| 30 Sep 20 | 77 | -35 | 29 | 27 |
| 30 Jun 20 | 74 | -32 | 27 | 26 |
| 31 Mar 20 | 70 | -29 | 25 | 24 |
| 31 Dec 19 | 65 | -25 | 22 | 22 |
| 30 Sep 19 | 60 | -22 | 19 | 19 |
| 30 Jun 19 | 55 | -19 | 16 | 18 |
| 31 Mar 19 | 48 | -20 | 13 | 17 |
| 31 Dec 18 | 38 | -20 | 11 | 14 |
| 31 Dec 17 | 9 | -24 | 10 | 10 |
Quality Earnings: 04X is currently unprofitable.
Growing Profit Margin: 04X is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 04X is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare 04X's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 04X is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: 04X has a negative Return on Equity (-83.66%), as it is currently unprofitable.